Immunome (NASDAQ:IMNM) Second Quarter 2024 Results Key Financial Results Revenue: US$2.36m (down 45% from 2Q 2023). Net loss: US$36.1m (loss widened by US$30.6m from 2Q 2023). US$0.60 loss per share ...
Source LinkImmunome (NASDAQ:IMNM) Second Quarter 2024 Results Key Financial Results Revenue: US$2.36m (down 45% from 2Q 2023). Net loss: US$36.1m (loss widened by US$30.6m from 2Q 2023). US$0.60 loss per share ...
Source Link
Comments